$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
瑞博西利是帕博西尼耐药后的治疗选择吗?
2025-10-19 11:44:20
Check Details
瑞博西林可以作为晚期乳腺癌的一线治疗用药吗?
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西利经FDA批准的适应症有哪些?
2025-10-19 11:44:20
Check Details
什么情况下可以采用CDK4/6抑制剂瑞博西林进行治疗?
2025-10-19 11:44:20
Check Details
瑞博西林在治疗HR+/HER2晚期或转移性乳腺癌这方面有着显著的疗效
2025-10-19 11:44:20
Check Details
瑞博西林对于晚期HER2阳性乳腺癌可显著延长患者总生存期
2025-10-19 11:44:20
Check Details
晚期乳腺癌一线治疗用药:CDK4/6抑制剂瑞博西利
2025-10-19 11:44:20
Check Details
乳腺癌患者如何正确使用瑞博西林进行治疗?
2025-10-19 11:44:20
Check Details
患者服用瑞博西林一个周期的费用
2025-10-19 11:44:20
Check Details
瑞博西利在绝经前HR阳性晚期乳腺癌一线治疗中有着巨大潜力
2025-10-19 11:44:20
Check Details
晚期乳腺癌服用瑞博西林进行治疗的效果
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西林多少钱一盒?国内能买到吗?
2025-10-19 11:44:20
Check Details
1
2
...
2002
2003
2004
2005
2006
2007
2008
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
2
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
3
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
4
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
5
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
6
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
7
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
8
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
9
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
10
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
11
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
12
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity